Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early axicabtagene ciloleucel for ultra-high risk large B-cell lymphoma
ACTRN12625000673448Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Dec 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Deliverability of axicabtagene ciloleucel. Started Dec 2025; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ACTRN12625000673448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000673448.